(Reuters) Billionaire investor William Ackman is set to face close questioning on Wednesday when he details his hedge fund’s biggest-ever quarterly loss and explains how he plans to handle the investment that led to the fall – Valeant Pharmaceuticals International.
Ackman’s Pershing Square Capital Management has blocked off one hour on Wednesday morning for him and his analysts to walk investors through exactly how one of its funds lost 25 percent in the first three months of 2016, including bets on Platform Specialty Products, Herbalife and Valeant.
